| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3981051 | Clinical Leukemia | 2007 | 6 Pages |
Abstract
Recent advances in chronic lymphocytic leukemia (CLL) biology have produced a plethora of new prognostic tests, many of which are becoming available commercially. At the same time, advances in therapy have improved response rates and extended the survival of patients with CLL. In this review, we present our current interpretation of the most important CLL prognostic markers in the context of modern combination chemotherapy and outline our recommendations for their use in the clinic.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
